Indian pharma exec: Compulsory licensing cost us $10B in investment

India-based Hetero Pharma's director adopted a heretical position in the local pharmaceutical industry when he said use of the compulsory licensing process has cost India $10 billion in potential investments. More from FiercePharmaAsia